Published 29 July 2026

London, UK - July 2026 | Strategic Revenue Insights Inc. - Personalized medicine is moving from a niche clinical option to a mainstream standard of care. According to new analysis from Strategic Revenue Insights, the global Personalized Medicines market stood at USD 900.0 billion in 2025 and is forecast to more than double, reaching USD 2.12 trillion by 2034, at a CAGR of 10.00%. The analysis is based on Strategic Revenue Insights' proprietary research framework, combining primary interviews across hospitals, diagnostic labs, and pharmaceutical manufacturers with secondary data across five global regions, led by lead analyst Anirudh Singh.

Key Takeaways

•       Global market size: USD 900.0 billion in 2025, rising to USD 2.12 trillion by 2034 (10.00% CAGR)

•       Personalized Therapeutics is the largest product segment; Personalized Nutrition & Wellness is the fastest-growing

•       Genomics & Sequencing leads by technology; AI-Driven Analytics is the fastest-growing technology segment

•       North America holds the largest regional share; Asia Pacific is the fastest-growing region

•       Roche, Illumina, and Thermo Fisher Scientific lead the competitive landscape

Full report access: https://www.strategicrevenueinsights.com/industry/personalized-medicines-market

Why the Market Is Accelerating

Chronic disease prevalence is the single biggest structural driver behind this growth. The World Health Organization attributes 71% of all deaths worldwide to chronic disease, a burden that is pushing health systems toward therapies matched to a patient's genetic and biomarker profile rather than one-size-fits-all treatment. That shift is reinforced by falling genomic sequencing costs, which have made it economically viable for a much broader set of hospitals and labs to fold genomic data into everyday treatment planning.

A second driver is the rise of AI-driven diagnostics. Where genomic testing identifies the raw biological signal, AI-driven analytics is what turns that signal into an actionable, individualized treatment plan at scale, a combination that is reshaping both diagnostic accuracy and drug development timelines.

Consumer-driven demand is a third, less-discussed force. Interest in personalized nutrition and wellness, powered by the same biomarker-based testing used in clinical settings, is pulling personalized health approaches beyond hospitals and into everyday consumer products.

Market Segmentation

By product type, the market spans Personalized Therapeutics, Companion Diagnostics, Personalized Medical Care & Devices, and Personalized Nutrition & Wellness. Personalized Therapeutics leads on the strength of targeted treatment demand, while Personalized Nutrition & Wellness is expanding fastest as consumers seek biomarker-informed dietary and wellness guidance.

By technology, Genomics & Sequencing anchors the market, with Proteomics and Pharmacogenomics supporting more precise drug-response and treatment-selection decisions. AI-Driven Analytics is the fastest-growing technology category, improving diagnostic precision and shortening the path from testing to treatment.

By application, Oncology represents the largest segment, driven by rising cancer incidence and the shift toward targeted, biomarker-guided therapies over conventional cytotoxic treatment. Rare & Genetic Diseases, Cardiovascular, Neurology & Psychiatry, Infectious Diseases, and Immunology round out the application landscape, each benefiting from more precise, genetically-informed treatment protocols.

By end use, Hospitals & Cancer Centers account for the largest share, followed by Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, and Academic Research Institutes, the last of which is growing quickly as research infrastructure investment expands globally.

Regional Outlook

North America leads the global market on the back of advanced healthcare infrastructure and early adoption of personalized medicine protocols. Asia Pacific is the fastest-growing region, driven by rising healthcare investment and expanding diagnostic infrastructure across the region's major economies. Europe, Latin America, and the Middle East & Africa are each building out genomic testing and biomarker-based diagnostic capacity at a steadier pace.

Competitive Landscape

Roche, Illumina, and Thermo Fisher Scientific lead the competitive field. Roche continues to invest in genomics and biomarker-based diagnostics to support targeted therapy development. Illumina holds a strong position in sequencing technology, underpinning much of the genomic data used across the industry. Thermo Fisher Scientific offers a broad portfolio spanning genomic testing, biomarker assays, and AI-driven analytics. Qiagen, Novartis, AstraZeneca, Myriad Genetics, Exact Sciences, Guardant Health, and Tempus AI round out a competitive field marked by heavy R&D investment and an active pace of strategic partnerships.

Market Restraints

Regulatory complexity remains the most significant barrier to entry, as evolving approval pathways for personalized therapies add cost and time to commercialization. High treatment cost is a second constraint, limiting patient access and slowing adoption relative to established, lower-cost treatment alternatives.

Related Reports

Companion Diagnostics Market - https://www.strategicrevenueinsights.com/industry/companion-diagnostics-market

Precision Oncology Market - https://www.strategicrevenueinsights.com/industry/precision-oncology-market

Genomics Market - https://www.strategicrevenueinsights.com/industry/genomics-market

 Pharmaceutical Stability Storage market - https://www.strategicrevenueinsights.com/category/healthcarehttps://www.strategicrevenueinsights.com/industry/pharmaceutical-stability-storage-market

Frequently Asked Questions

What is driving growth in the Personalized Medicines market?

Growth is driven by rising chronic disease prevalence, falling genomic sequencing costs, and the integration of AI-driven analytics into diagnostics and treatment planning.

Which region leads the Personalized Medicines market?

North America holds the largest market share, supported by advanced healthcare infrastructure. Asia Pacific is the fastest-growing region.

Who are the key players in the Personalized Medicines market?

Leading companies include Roche, Illumina, Thermo Fisher Scientific, Qiagen, Novartis, AstraZeneca, Myriad Genetics, Exact Sciences, Guardant Health, and Tempus AI.

What is the projected market size by 2034?

The market is projected to reach USD 2.12 trillion by 2034, up from USD 900.0 billion in 2025, at a CAGR of 10.00%.

About Strategic Revenue Insights Inc.

Strategic Revenue Insights Inc., a subsidiary of SRI Consulting Group Ltd, provides syndicated market research and strategic consulting across Healthcare, Packaging, Chemicals, Energy, Aerospace & Defense, and other sectors, with a catalog of over 65,000 reports. The firm is headquartered in London, United Kingdom.

Media Contact Information

Company Name: Strategic Revenue Insights Inc.

Contact Person: Rohit Bhisey

Email: sales@strategicrevenueinsights.com

Phone: +44-787-740-3352

Address: Suite 10, Capital House, 61 Amhurst Road, London, E8 1LL, United Kingdom

Corporate Websites

www.strategicrevenueinsights.com

www.strategicpackaginginsights.com

www.sriconsultinggroupltd.com